INVEST IN THE FUTURE OF PAIN RELIEF
Pain is universal. It disrupts work, time with family, and quality of life. Through innovations, we can make a difference.
VIRPAX Pharmaceuticals is collaborating with the best minds of the pharmaceutical industry. Working alongside these leaders, we can improve pain management and target pain at its source.
Partner with us as we develop the next generation of pharmaceutical products that can minimize pain and improve people’s lives.
BECOME A PARTNER
484.880.4588 info@virpaxpharma.com
Chester County drug developer Virpax working on ‘molecular mask’ to combat Covid-19
By John George – Senior Reporter, Philadelphia Business Journal Virpax Pharmaceuticals Inc. has joined the battle against Covid-19 through a new technology licensing agreement with a London life sciences company. The Chester County drug developer signed the deal with Nanomerics Ltd. for the exclusive North America rights to [...]
Virpax Enters into an NIH Collaboration to Further Develop NES100 for Acute and Chronic Non-Cancer Pain
Announces CRADA with National Center for Advancing Translational Sciences Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the [...]
Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections Virpax Pharmaceuticals Inc. (“Virpax”), today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray (MMS019) for the prevention of seasonal influenza [...]